Patents by Inventor Hye Won Kang

Hye Won Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11841369
    Abstract: The present invention relates to a method of improving the quality of therapeutic cells by real-time glutathione monitoring.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: December 12, 2023
    Assignee: Cell2In, Inc.
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Gwang Mo Yang, Ji Woong Shin, Hye Won Kang, Yong Hwan Kim, Myung Jin Kim
  • Publication number: 20230080144
    Abstract: The present invention relates to a real-time fluorescence imaging sensor for measuring glutathione in the endoplasmic reticulum (ER) and a method for producing same. More specifically, the present invention relates to a new compound for measuring glutathione in the endoplasmic reticulum (ER), a method for producing the new compound, a real-time imaging sensor for measuring glutathione in the endoplasmic reticulum (ER) comprising the new compound, a method for producing same, and a method for measuring glutathione in the endoplasmic reticulum (ER) by using the imaging sensor.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 16, 2023
    Inventors: Heun Soo Kang, Hye Mi Kim, Gwang Mo Kim, Yeji Kim, Ji Woong Shin, Hye Won Kang, Yong Hwan Kim, Ki Hang Choi, Su-Hyeon Min
  • Patent number: 11499978
    Abstract: The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: November 15, 2022
    Assignee: CELL2IN, INC.
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Gwang Mo Yang, Ji Woong Shin, Hye Won Kang, Yong Hwan Kim, Myung Jin Kim
  • Publication number: 20210275596
    Abstract: The present invention relates to a therapeutic stem cell composition comprising a stem cell in which the expression level of any one or more genes selected from the group consisting of ACAN, SOX9, AP2, RUNX2, OCN, ALP, OCT4, SOX2, CXCR4, cMET, PDGFRA, PDGFRB, VEGF-R1, VEGF-R2, CSF-1, IDO2, Sox2, Nanog, cMyc, Klf2, Klf4, Rex1, Esrrb, Neurog1, Neurod1, Nkx2.2, Ascl2, Gfap, S100b, Olig2, Neurog2, T, Nkx2.5, Esrrbb, Klf2, Klf4, cTnT, a-Actin, Mlc2v and Runx1 is higher or lower than the expression level of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene.
    Type: Application
    Filed: July 20, 2018
    Publication date: September 9, 2021
    Inventors: Heun Soo KANG, Hye Mi KIM, Ji Eun SONG, Yingfu YIN, Ji Woong SHIN, Hye Won KANG, Yong Hwan KIM
  • Publication number: 20210003582
    Abstract: The present invention relates to a method of improving the quality of therapeutic cells by real-time glutathione monitoring.
    Type: Application
    Filed: November 28, 2018
    Publication date: January 7, 2021
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Gwang Mo Yang, Ji Woong Shin, Hye Won Kang, Yong Hwan Kim, Myung Jin Kim
  • Publication number: 20200363422
    Abstract: The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 19, 2020
    Inventors: Heun Soo Kang, Hye Mi Kim, Ji Eun Song, Gwang Mo Yang, Ji Woong Shin, Hye Won Kang, Yong Hwan Kim, Myung Jin Kim
  • Publication number: 20200315573
    Abstract: An ultrasound diagnostic apparatus in accordance with one aspect of the disclosure includes: a table configured to mount at least one probe; a first sensor configured to detect a type information of the probe and a mounting state of the probe; a driver configured to generate a driving force for moving the table; a second sensor configured to detect a position of the table; and a controller configured to control the driver based on detection results of the first sensor and the second sensor.
    Type: Application
    Filed: March 23, 2020
    Publication date: October 8, 2020
    Inventors: Hye won Kang, Gi seok Sung, Yong Hyun Kim, Choong Mo Yang, Tae Ho Lee, Sok Jae Shin, Ku II Jang, Min Ho Heo
  • Patent number: 10664023
    Abstract: An electronic device includes a bracket having a through hole, a first circuit board and a second circuit board which are disposed below the bracket. The second circuit board is electrically connected with the first circuit board, and a first module and a second module are disposed above the bracket. The first module and the second module are electrically connected with the first circuit board via a wiring structure passing through the through hole.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 26, 2020
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Tae Sik Kim, Myung Jae Jo, Hye Won Kang, Ja Myeong Koo, Mu Jin Kim, Jeong Woon Koo, Dae Heon Kwon, Sei Neu Park, Won Hyun Park, Jae Young Yun
  • Publication number: 20180017999
    Abstract: An electronic device includes a bracket having a through hole, a first circuit board and a second circuit board which are disposed below the bracket. The second circuit board is electrically connected with the first circuit board, and a first module and a second module are disposed above the bracket. The first module and the second module are electrically connected with the first circuit board via a wiring structure passing through the through hole.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 18, 2018
    Inventors: Tae Sik KIM, Myung Jae JO, Hye Won KANG, Ja Myeong KOO, Mu Jin KIM, Jeong Woon KOO, Dae Heon KWON, Sei Neu PARK, Won Hyun PARK, Jae Young YUN
  • Patent number: 9720864
    Abstract: A flexible server system includes an embedded processor, one or more processor boards, one or more storage boards, and a switch including a plurality of ports. The embedded processor, the one or more processor boards, and the one or more storage boards are connected to a corresponding one of the plurality of ports. The embedded processor, the one or more processor boards, the one or more storage boards, and the switch each include a peripheral component interconnect express (PCIe) interface. The one or more processor boards and the one or more storage boards are connected to the switch through connectors where each of the corresponding connectors have a same size. The embedded processor controls the switch to route a packet from one of the plurality of ports to another one of the plurality of ports.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: August 1, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bum-Jun Kim, Woo-Seok Chang, Hye-Won Kang, Em-Hwan Kim, Kwang-Hyun La, Su-Hwan Park, Jang-Won Lee
  • Patent number: 9701942
    Abstract: The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1? (IL-1?), Interleukin-6 (IL-6), Tumor necrosis factor-? (TNF-?), Interferon-? (IFN-?), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: July 11, 2017
    Assignee: JW CREAGENE INC.
    Inventors: Yoon Lee, Hye-Won Kang, Seung-Soo Han, Young-Mok Kim, Yong-Soo Bae, Seo-Hee Ahn
  • Patent number: 9173841
    Abstract: The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: November 3, 2015
    Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
    Inventors: Hye Won Kang, Min Hyo Seo, Sa Won Lee, Bong Oh Kim, Eun Kyung Choi, Seong Yun Jeong, Ha Na Woo
  • Publication number: 20150143018
    Abstract: A flexible server system includes an embedded processor, one or more processor boards, one or more storage boards, and a switch including a plurality of ports. The embedded processor, the one or more processor boards, and the one or more storage boards are connected to a corresponding one of the plurality of ports. The embedded processor, the one or more processor boards, the one or more storage boards, and the switch each include a peripheral component interconnect express (PCIe) interface. The one or more processor boards and the one or more storage boards are connected to the switch through connectors where each of the corresponding connectors have a same size. The embedded processor controls the switch to route a packet from one of the plurality of ports to another one of the plurality of ports.
    Type: Application
    Filed: August 11, 2014
    Publication date: May 21, 2015
    Inventors: Bum-Jun KIM, Woo-Seok CHANG, Hye-Won KANG, Em-Hwan KIM, Kwang-Hyun LA, Su-Hwan PARK, Jang-Won LEE
  • Publication number: 20150125956
    Abstract: The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1? (IL-1?), Interleukin-6 (IL-6), Tumor necrosis factor-? (TNF-?), Interferon-? (IFN-?), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 7, 2015
    Applicant: JW CREAGENE INC.
    Inventors: Yoon Lee, Hye-Won Kang, Seung-Soo Han, Young-Mok Kim, Yong-Soo Bae, Seo-Hee Ahn
  • Publication number: 20140212462
    Abstract: The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.
    Type: Application
    Filed: March 31, 2014
    Publication date: July 31, 2014
    Applicant: SAMYANG BIOPHARMECEUTICALS CORPORATION
    Inventors: Hye Won KANG, Min Hyo SEO, Sa Won LEE, Bong Oh KIM, Eun Kyung CHOI, Seong Yun JEONG, Ha Na WOO
  • Publication number: 20120276169
    Abstract: The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.
    Type: Application
    Filed: December 29, 2010
    Publication date: November 1, 2012
    Inventors: Hye Won Kang, Min Hyo Seo, Sa Won Lee, Bong Oh Kim, Eun Kyung Choi, Seong Yun Jeong, Ha Na Woo
  • Publication number: 20110224151
    Abstract: Disclosed are a polymer micelle composition for treatment of resistant cancer cells that contains an amphiphilic double block copolymer and taxane and a P-glycoprotein inhibitor of cyclosporin as its active ingredients, and a method of preparing the same. Said polymer micelle composition for treatment of cancer resistant cells is accumulated in cancer tissue at high concentrations, and has the advantages that it exhibits superior anti-cancer effects for the cancer cells that have exhibited resistance due to over-expression of P-glycoprotein by the taxane anticancer agent in said cancer tissue, and does not cause hypersensitive reactions due to the use of a solubilizer.
    Type: Application
    Filed: November 23, 2009
    Publication date: September 15, 2011
    Applicant: SAMYANG CORPORATION
    Inventors: Hye-Won Kang, Min Hyo Seo, Bong Oh Kim
  • Publication number: 20100008998
    Abstract: The present invention relates to a nanoparticle composition comprising a camptothecin derivative, solid polyethyleneglycol and an anti-associative agent, and the process for preparing the same. Specifically, the present invention provides a composition comprising a nanoparticle of the camptothecin derivative, which is prepared by solid-dispersing the poorly water soluble camptothecin derivative in polyethyleneglycol and dissolving the solid dispersions in an aqueous solution containing an anti-associative agent. The composition of the present invention stabilizes the camptothecin derivative lactone form in body fluid for effective anticancer activity.
    Type: Application
    Filed: September 20, 2007
    Publication date: January 14, 2010
    Applicant: SAMYANG CORPORATION
    Inventors: Hye Won Kang, Eun Young Yim, Min Hyo Seo
  • Publication number: 20080260850
    Abstract: Delivery system for bioactive agents on the basis of a polymeric drug carrier formed from compositions comprising an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block having a terminal hydroxyl group substituted with a tocopherol or cholesterol group, and a polylactic acide derivative wherein one end of the polylactic acid is covalently bound to at least one carboxyl group. The carboxyl group of the polylactic acid derivative may be fixed with a di- or trivalent metal ion, which is obtained by adding the di- or trivalent metal ion to the polymeric composition.
    Type: Application
    Filed: May 6, 2005
    Publication date: October 23, 2008
    Applicant: SAMYANG CORPORATION
    Inventors: Yil-Woong Yi, Sa-Won Lee, Jeong-Il Yu, Dong-Hoon Chang, Min-Hyo Seo, Hye-Won Kang, Jae-Hong Kim
  • Publication number: 20070254905
    Abstract: The present invention relates to a pharmaceutical formulation for increasing the solubility of a 10-hydroxycamptothecin compound in non-aqueous polar solvent, comprising a 10-hydroxycamptothecin compound and an amine compound whose pKa value is 7.4 or more. By using the formulation according to the present invention, the solubility of the 10-hydroxycamptothecin compound for non-aqueous polar solvent is increased, while maintaining the active lactone form of 10-hydroxycamptothecin.
    Type: Application
    Filed: November 4, 2005
    Publication date: November 1, 2007
    Applicant: SAMYANG CORPORATION
    Inventors: Min-Hyo Seo, Hye-Won Kang